MarketWise (MKTW) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
6 Nov, 2025Executive summary
Net revenue for Q3 2025 was $81.3 million, down 16.4% year-over-year, with net income of $17.9 million and a 22.0% margin, primarily due to the wind down of Legacy Research brands and lower subscription revenue.
Cash from operating activities improved to $2.2 million in Q3 2025, up $8.0 million from Q3 2024, with year-to-date CFFO up $49.9 million.
Cash and cash equivalents stood at $50.5 million as of September 30, 2025, with no debt outstanding.
Announced quarterly and special dividends totaling $0.40 per Class A share in October 2025, bringing FY 2025 dividends to $1.90 per share (13% yield).
A proposal to acquire all outstanding equity at $17.25 per share was received in October 2025, leading to suspension of share repurchases.
Financial highlights
Total net revenue for the nine months ended September 30, 2025 was $244.7 million, down 21.4% year-over-year.
Net income for the nine months was $50.1 million, down from $66.7 million in the prior year.
EBITDA for Q3 2025 was $18.9 million, down 18.2% year-over-year; for the nine months ended September 30, 2025: $52.1 million.
Free cash flow for Q3 2025 was $1.7 million; year-to-date free cash flow was $20.7 million.
Earnings per share (diluted) for Q3 2025 was $0.87.
Outlook and guidance
FY 2025 billings expected to reach $260 million, exceeding the original $250 million target.
FY 2025 CFFO expected to be approximately $31 million, above the $30 million target.
FY 2026 preliminary targets: billings of $290 million (10% growth), CFFO of $45 million (50% YoY increase), and dividends of $1.60 per share.
Management expects continued improvement in operating cash flows and plans to invest in operational efficiency and product development.
No significant tax distributions or TRA payments are expected in Q4 2025.
Latest events from MarketWise
- Q4 2025 billings surged 42% YoY, FY 2026 guidance raised, and dividends increased.MKTW
Q4 20256 Mar 2026 - Q4 2024 saw a return to billings growth, improved margins, and renewed strategic focus.MKTW
Emerging Growth Conference 7810 Jan 2026 - Shareholders to vote on director elections, equity plan amendment, and new auditor ratification.MKTW
Proxy Filing1 Dec 2025 - Vote on reverse stock split and share reduction to maintain Nasdaq listing and streamline capital structure.MKTW
Proxy Filing1 Dec 2025 - Vote to approve a 1-for-20 reverse stock split and reduce authorized shares for Nasdaq compliance.MKTW
Proxy Filing1 Dec 2025 - Key votes include director elections, incentive plan amendment, and auditor ratification.MKTW
Proxy Filing1 Dec 2025 - Q2 2025 saw revenue and subscribers fall, but cash flow, billings, and capital returns strengthened.MKTW
Q2 20257 Aug 2025 - Net income rose to $22.7M in Q3 2024 despite sharp declines in revenue and subscribers.MKTW
Q3 202413 Jun 2025 - Net income surged to $21.2M in Q2 2024, while billings fell 40% amid Legacy Research wind-down.MKTW
Q2 202413 Jun 2025